Tirzepatide Discontinuation Linked to Weight Regain and Metabolic Reversal

Post-hoc analysis by Deborah B. Horn found stopping tirzepatide reversed cardiometabolic improvements, with increases in BP, lipids, HbA1c, insulin, and waist circumference by week 88.
Long-term anti-obesity treatment may sustain weight and cardiometabolic benefits, but longer follow-up is needed.
Metabolic markers rose with weight regain, including 6.8–10.4 mm Hg BP increase and 46.2% fasting insulin rise.
Clinicians should warn patients of weight regain and loss of cardiometabolic benefits if medication is stopped.
Trial enrolled 308 adults with obesity or overweight (BMI criteria) on 15-mg tirzepatide dose.

Health | Medication | Obesity

USA

Deborah B. Horn | Elizabeth Oczypok | Timothy S. Anderson

1 month ago